CyanVac selects Exothera for the development and GMP manufacturing of its COVID-19 intranasal vaccine candidate for phase III clinical trial in Europe and the US.

March 24th 2021

Exothera will be responsible for the fast-track development of a manufacturing process for CyanVac's COVID-19 vaccine candidate, CVXGA1, using the unique scale-X™ platform. This cutting-edge platform and Exothera’s leadership in process development will enable CyanVac to produce GMP clinical trial material (CTM) in 2021 for planned phase 3 clinical studies.  Please discover the press release here